Skip to content

Innoviva, Inc. INVA Debt-to-equity

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Insmed logo
InsmedINSM
0.8×-10.7×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
1.4×+1.1×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
0.0×

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s debt-to-equity?
Innoviva, Inc. (INVA) reported debt-to-equity of 0.2× in Q1 2026.
What is the long-term trend for Innoviva, Inc.'s debt-to-equity?
Over 4 years (2020 to 2025), Innoviva, Inc.'s debt-to-equity has grown at a -24.7% compound annual growth rate (CAGR), from 0.7× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.